Top

Published in:

Open Access 01-12-2023 | Biomarkers | Research

Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study

Authors: Xinyue Ma, Shu Huang, Huiqin Shi, Rui Luo, Bei Luo, Zhenju Tan, Lei Shi, Wei Zhang, Weixing Yang, Xiaolin Zhong, Muhan Lü, Xia Chen, Xiaowei Tang

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

Acyl-CoA-binding domain-containing 3 (ACBD3) is a multifunctional protein, that plays essential roles in cellular signaling and membrane domain organization. Although the precise roles of ACBD3 in various cancers remain unclear. Thus, we aimed to determine the diverse roles of ACBD3 in pan-cancers.

Methods

Relevant clinical and RNA-sequencing data for normal tissues and 33 tumors from The Cancer Genome Atlas (TCGA) database, the Human Protein Atlas, and other databases were applied to investigate ACBD3 expression in various cancers. ACBD3-binding and ACBD3-related target genes were obtained from the STRING and GEPIA2 databases. The possible functions of ACBD3-binding genes were explored using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. We also applied the diagnostic value and survival prognosis analysis of ACBD3 in pan-cancers using R language. The mutational features of ACBD3 in various TCGA cancers were obtained from the cBioPortal database.

Results

When compared with normal tissues, ACBD3 expression was statistically upregulated in eleven cancers and downregulated in three cancers. ACBD3 expression was remarkably different among various pathological stages of tumors, immune and molecular subtypes of cancers, cancer phosphorylation levels, and immune cell infiltration. The survival of four tumors was correlated with the expression level of ACBD3, including pancreatic adenocarcinoma, adrenocortical carcinoma, sarcoma, and glioma. The high accuracy in diagnosing multiple tumors and its correlation with prognosis indicated that ACBD3 may be a potential biomarker of pan-cancers.

Conclusion

According to our pan-cancer analysis, ACBD3 may serve as a remarkable prognostic and diagnostic biomarker of pan-cancers as well as contribute to tumor development. ACBD3 may also provide new directions for cancer treatment targets in the future.

Available only for authorised users

Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S, IASLC Pathology Committee. Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2022;17(12):1335–54. https://doi.org/10.1016/j.jtho.2022.09.109.CrossRefPubMed

Zhong H, Shi Q, Wen Q, Chen J, Li X, Ruan R, Zeng S, Dai X, Xiong J, Li L, Lei W, Deng J. Pan-cancer analysis reveals potential of FAM110A as a prognostic and immunological biomarker in human cancer. Front Immunol. 2023;27(14):1058627. https://doi.org/10.3389/fimmu.2023.1058627.CrossRef

Pradat Y, Viot J, Yurchenko AA, Gunbin K, Cerbone L, Deloger M, Grisay G, Verlingue L, Scott V, Padioleau I, Panunzi L, Michiels S, Hollebecque A, Jules-Clément G, Mezquita L, Lainé A, Loriot Y, Besse B, Friboulet L, André F, Cournède PH, Gautheret D, Nikolaev SI. Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer. Cancer Discov. 2023;13(5):1116–43. https://doi.org/10.1158/2159-8290.CD-22-0966.CrossRefPubMedPubMedCentral

Islinger M, Costello JL, Kors S, Soupene E, Levine TP, Kuypers FA, et al. The diversity of ACBD proteins - From lipid binding to protein modulators and organelle tethers. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118675. https://doi.org/10.1016/j.bbamcr.2020.118675.CrossRefPubMedPubMedCentral

Houghton-Gisby J, Kerslake R, Karteris E, Mokbel K, Harvey AJ. ACBD3 bioinformatic analysis and protein expression in breast cancer cells. Int J Mol Sci. 2022;23(16):8881. https://doi.org/10.3390/ijms23168881.CrossRefPubMedPubMedCentral

Yue X, Qian Y, Gim B, Lee I. Acyl-CoA-binding domain-containing 3 (ACBD3; PAP7; GCP60): a multi-functional membrane domain organizer. Int J Mol Sci. 2019;20(8):2028. https://doi.org/10.3390/ijms20082028.CrossRefPubMedPubMedCentral

Huang H, Liao X, Zhu G, Han C, Wang X, Yang C, et al. Acyl-CoA binding domain containing 4 polymorphism rs4986172 and expression can serve as overall survival biomarkers for hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy. Pharmgenomics Pers Med. 2022;29(15):277–300. https://doi.org/10.2147/PGPM.S349350.PMID:35378899;PMCID:PMC8976523.CrossRef

Neess D, Bek S, Engelsby H, Gallego SF, Færgeman NJ. Long-chain acyl-CoA esters in metabolism and signaling: role of acyl-CoA binding proteins. Prog Lipid Res. 2015;59:1–25. https://doi.org/10.1016/j.plipres.2015.04.001.CrossRefPubMed

Yue X, Qian Y, Zhu L, Gim B, Bao M, Jia J, Jing S, Wang Y, Tan C, Bottanelli F, Ziltener P, Choi S, Hao P, Lee I. ACBD3 modulates KDEL receptor interaction with PKA for its trafficking via tubulovesicular carrier. BMC Biol. 2021;19(1):194. https://doi.org/10.1186/s12915-021-01137-7.PMID:34493279;PMCID:PMC8424950.CrossRefPubMedPubMedCentral

10.

Liao J, Guan Y, Chen W, Shi C, Yao D, Wang F, et al. ACBD3 is required for FAPP2 transferring glucosylceramide through maintaining the Golgi integrity. J Mol Cell Biol. 2019;11(2):107–17. https://doi.org/10.1093/jmcb/mjy030.CrossRefPubMed

11.

Huang Y, Yang L, Pei YY, Wang J, Wu H, Yuan J, et al. Overexpressed ACBD3 has prognostic value in human breast cancer and promotes the self-renewal potential of breast cancer cells by activating the Wnt/beta-catenin signaling pathway. Exp Cell Res. 2018;363(1):39–47. https://doi.org/10.1016/j.yexcr.2018.01.003.CrossRefPubMed

12.

Zheng Y, Pei Y, Tang R, Zhou X, Feng Z, Li D, et al. ACBD3 is up-regulated in gastric cancer and promotes cell cycle G1-to-S transition in an AKT-dependent manner. Exp Cell Res. 2021;406(2):112752. https://doi.org/10.1016/j.yexcr.2021.112752.CrossRefPubMed

13.

Kakiuchi S, Daigo Y, Ishikawa N, Furukawa C, Tsunoda T, Yano S, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). Hum Mol Genet. 2004;13(24):3029–43. https://doi.org/10.1093/hmg/ddh331.CrossRefPubMed

14.

Ganini C, Amelio I, Bertolo R, Bove P, Buonomo OC, Candi E, Cipriani C, Di Daniele N, Juhl H, Mauriello A, Marani C, Marshall J, Melino S, Marchetti P, Montanaro M, Natale ME, Novelli F, Palmieri G, Piacentini M, Rendina EA, Roselli M, Sica G, Tesauro M, Rovella V, Tisone G, Shi Y, Wang Y, Melino G. Global mapping of cancers: the Cancer Genome Atlas and beyond. Mol Oncol. 2021;15(11):2823–40. https://doi.org/10.1002/1878-0261.13056.CrossRefPubMedPubMedCentral

15.

Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER 3rd, Kalocsay M, Jané-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M, Golji J, Porter DA, Rejtar T, Wang YK, Kryukov GV, Stegmeier F, Erickson BK, Garraway LA, Sellers WR, Gygi SP. Quantitative proteomics of the cancer cell line encyclopedia. Cell. 2020;180(2):387-402.e16. https://doi.org/10.1016/j.cell.2019.12.023.CrossRefPubMedPubMedCentral

16.

Gong K, Zhou H, Liu H, Xie T, Luo Y, Guo H, et al. Identification and integrate analysis of key biomarkers for diagnosis and prognosis of non-small cell lung cancer based on bioinformatics analysis. Technol Cancer Res Treat. 2021;20:15330338211060202. https://doi.org/10.1177/15330338211060202.CrossRefPubMedPubMedCentral

17.

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14. https://doi.org/10.1093/nar/gkaa407.CrossRefPubMedPubMedCentral

18.

Wu P, Heins ZJ, Muller JT, Katsnelson L, de Bruijn I, Abeshouse AA, et al. Integration and analysis of cptac proteomics data in the context of cancer genomics in the cBioportal. Mol Cell Proteomics. 2019;18(9):1893–8. https://doi.org/10.1074/mcp.TIR119.001673.CrossRefPubMedPubMedCentral

19.

Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–2. https://doi.org/10.1093/bioinformatics/btz210.CrossRefPubMed

20.

Zhang C, Guo C, Li Y, Liu K, Zhao Q, Ouyang L. Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis. Front Cell Dev Biol. 2021;2(9): 726656. https://doi.org/10.3389/fcell.2021.726656.CrossRef

21.

Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 2013;41:D991–5.CrossRefPubMed

22.

Modhukur V, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics. 2018;10(3):277–88. https://doi.org/10.2217/epi-2017-0118.CrossRefPubMed

23.

Xing C, Wang Z, Zhu Y, Zhang C, Liu M, Hu X, et al. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. Int J Med Sci. 2021;18(3):672–84. https://doi.org/10.7150/ijms.53243.PMID:33437202;PMCID:PMC7797531.CrossRefPubMedPubMedCentral

24.

Zhang X. Alterations of Golgi structural proteins and glycosylation defects in cancer. Front Cell Dev Biol. 2021;12(9): 665289. https://doi.org/10.3389/fcell.2021.665289.CrossRef

25.

Ali OM, El Amin HA, Sharkawy YL, Mohamed Ali AA, Kholef EFM, Elsewify WAE. Golgi protein 73 versus alpha-fetoprotein as a new biomarker in early diagnosis of hepatocellular carcinoma. Int J Gen Med. 2020;18(13):193–200. https://doi.org/10.2147/IJGM.S253622.CrossRef

26.

Bajaj R, Warner AN, Fradette JF, Gibbons DL. Dance of the Golgi: understanding Golgi dynamics in cancer metastasis. Cells. 2022;11(9):1484. https://doi.org/10.3390/cells11091484.PMID:35563790;PMCID:PMC9102947.CrossRefPubMedPubMedCentral

27.

Ahmed MB, Alghamdi AAA, Islam SU, Lee JS, Lee YS. cAMP signaling in cancer: a PKA-CREB and EPAC-centric approach. Cells. 2022;11(13):2020. https://doi.org/10.3390/cells11132020.PMID:35805104;PMCID:PMC9266045.CrossRefPubMedPubMedCentral

28.

Huang F, Ma G, Zhou X, Zhu X, Yu X, Ding F, et al. Depletion of LAMP3 enhances PKA-mediated VASP phosphorylation to suppress invasion and metastasis in esophageal squamous cell carcinoma. Cancer Lett. 2020;1(479):100–11. https://doi.org/10.1016/j.canlet.2020.03.014.CrossRef

29.

Jiang K, Yao G, Hu L, Yan Y, Liu J, Shi J, et al. MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling. Cell Death Dis. 2020;11(4):230. https://doi.org/10.1038/s41419-020-2381-8.PMID:32286266;PMCID:PMC7156523.CrossRefPubMedPubMedCentral

30.

Zhang H, Yang S, Wang J, Jiang Y. Blockade of AMPK-mediated cAMP-PKA-CREB/ATF1 signaling synergizes with aspirin to inhibit hepatocellular carcinoma. Cancers (Basel). 2021;13(7):1738. https://doi.org/10.3390/cancers13071738.PMID:33917483;PMCID:PMC8038809.CrossRefPubMed

31.

Kilanowska A, Ziółkowska A, Stasiak P, Gibas-Dorna M. cAMP-dependent signaling and ovarian cancer. Cells. 2022;11(23):3835. https://doi.org/10.3390/cells11233835.CrossRefPubMedPubMedCentral

32.

Singh V, Ram M, Kumar R, Prasad R, Roy BK, Singh KK. Phosphorylation: implications in cancer. Protein J. 2017;36(1):1–6. https://doi.org/10.1007/s10930-017-9696-z.CrossRefPubMed

33.

Ardito F, Giuliani M, Perrone D, Troiano G, Lo ML. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med. 2017;40(2):271–80. https://doi.org/10.3892/ijmm.2017.3036.CrossRefPubMedPubMedCentral

34.

Biffi G, Tuveson DA. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147–76. https://doi.org/10.1152/physrev.00048.2019.CrossRefPubMed

Title: Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study
Authors: Xinyue Ma
Shu Huang
Huiqin Shi
Rui Luo
Bei Luo
Zhenju Tan
Lei Shi
Wei Zhang
Weixing Yang
Xiaolin Zhong
Muhan Lü
Xia Chen
Xiaowei Tang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Biomarkers
Sarcoma
Glioblastoma
Glioblastoma
Glioblastoma
Adrenocortical Carcinoma
Breast Cancer
Breast Cancer
Pheochromocytoma and Paraganglioma
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01576-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Overexpression of TMEM79 combined with SMG5 is related to prognosis, tumor immune infiltration and drug sensitivity in hepatocellular carcinoma

TCAP gene is not a common cause of cardiomyopathy in Iranian patients

Different expression and prognostic value of troponin in ischemic cardiomyopathy and non-ischemic dilated cardiomyopathy

Sleep disturbance increases the risk of severity and acquisition of COVID-19: a systematic review and meta-analysis

Association of balance impairment with risk of incident cardiovascular diseases among older adults

Nanocrystal-induced chronic tubular-nephropathy in tropical countries: diagnosis, mitigation, and eradication